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Falling Threshold for Treatment of Borderline Elevated
Thyrotropin Levels—Balancing Benefits and Risks
Evidence From a Large Community-Based Study
Peter N. Taylor, MSc, MRCP; Ahmed Iqbal, MRCP; Caroline Minassian, MSc; Adrian Sayers, MSc;
Mohd S. Draman, MRCP; Rosemary Greenwood, MSc; William Hamilton, MD; Onyebuchi Okosieme, MD, FRCP;
Vijay Panicker, PhD; Sara L. Thomas, PhD; Colin Dayan, PhD, FRCP
IMPORTANCE Rates of thyroid hormone prescribing in the United States and the United
Kingdom have increased substantially. If some of the increase is due to lowering the
thyrotropin threshold for treatment, this may result in less benefit and greater harm.
OBJECTIVE To define trends in thyrotropin levels at the initiation of levothyroxine sodium
therapy and the risk of developing a suppressed thyrotropin level following treatment.
DESIGN, SETTING, PARTICIPANTS, AND EXPOSURE Retrospective cohort study using data from
the United Kingdom Clinical Practice Research Datalink. Among 52 298 individuals who
received a prescription for levothyroxine between January 1, 2001, and October 30, 2009,
we extracted data about the thyrotropin level before levothyroxine therapy initiation, clinical
symptoms, and thyrotropin levels up to 5 years after levothyroxine was initiated. We
excluded persons who had a history of hyperthyroidism, pituitary disease, or thyroid surgery;
those whowere taking thyroid-altering medication or if the levothyroxine prescription was
related to pregnancy; and those who did not have a thyrotropin level measured within 3
months before the initiation of levothyroxine.
MAIN OUTCOMES ANDMEASURES Themedian thyrotropin level at the time of the index
levothyroxine prescription, the odds of initiation of levothyroxine therapy at thyrotropin
levels of 10.0mIU/L or less, and the age-stratified odds of developing a low or suppressed
thyrotropin level after levothyroxine therapy.
RESULTS Between 2001 and 2009, themedian thyrotropin level at the initiation of
levothyroxine therapy fell from 8.7 to 7.9mIU/L. The odds ratio for prescribing levothyroxine
at thyrotropin levels of 10.0mIU/L or less in 2009 compared with 2001 (adjusted for changes
in population demographics) was 1.30 (95% CI, 1.19-1.42; P < .001). Older individuals and
individuals with cardiac risk factors had higher odds of initiation of levothyroxine therapy with
a thyrotropin level 10.0mIU/L or less. At 5 years after levothyroxine initiation, 5.8% of
individuals had a thyrotropin level of <0.1 mIU/L. Individuals with depression or tiredness at
baseline had increased odds of developing a suppressed thyrotropin level, whereas
individuals with cardiac risk factors (eg, atrial fibrillation, diabetes mellitus, hypertension, and
raised lipid levels) did not.
CONCLUSIONS AND RELEVANCE We observed a trend toward levothyroxine treatment of
moremarginal degrees of hypothyroidism and a substantial risk of developing a suppressed
thyrotropin level following therapy. Large-scale prospective studies are required to assess the
risk-benefit ratio of current practice.
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P rimary hypothyroidism is one of the most commonchronicdisorders inWesternpopulations1,2 and is largelymanaged inprimarycare.3,4Levothyroxinesodiumpre-
scriptions in theUnited States have increased substantially in
recentyears (from49.8million in2006to70.5million in2010).5
A similar increase has been observed in England and Wales,
with levothyroxine prescriptions rising from 17.1 million (in
2006) to 23.4 million (in 2010),6 up from only 7 million pre-
scriptions in 1998 data.7,8
Several factorshaveprobablycontributedto this rise. InEn-
gland andWales, a proportionmay be attributed to a fall in the
meandurationofprescriptionsfrom60to45days.8Thyroidfunc-
tion testinghas also increased substantially,9,10 and inanyyear
18%to25%of individualshavetheir thyroidfunctiontested,4,9,11
likelyresulting in increasedcasefinding.However,anadditional
factormay be a lowering of the thyrotropin threshold atwhich
levothyroxine is initiated. This practicewould be important to
identifybecause itmightbeassociatedwithmoremarginalben-
efitsandwith increasedrelativeriskofpatientharm.Theresults
ofstudiespublishedbefore2001suggestedthatbetween15%and
20%of individuals taking levothyroxineareovertreatedandde-
velop a low thyrotropin level,12,13 most likely because of inad-
equatemonitoring.Overtreatmentisassociatedwithanincreased
risk of fractures14 and atrial fibrillation.15
American Thyroid Association guidelines16 recommend
consideration of levothyroxine therapy at thyrotropin levels
of 10.0mIU/L or lesswhen there are clear symptoms of hypo-
thyroidism,positive thyroidautoantibodies,orevidenceofath-
erosclerotic cardiovascular disease or heart failure (evidence
level B). Data from Scotland in 2001 indicated that most pa-
tients had levothyroxine initiated at thyrotropin levels of 10.0
mIU/Lor less,with45%to48%ofpatientshaving therapycom-
menced with a thyrotropin level less than 6.0 mIU/L.10
In this study,we used a largeUnitedKingdom (UK) popu-
lation-based database to examine trends in thyrotropin lev-
els beforeandafter levothyroxine therapy initiation since2001
and assessed the potential for adverse outcomes from cur-
rent practice.
Methods
Regulatory Approval
Access to theGeneral PracticeResearchDatabase (GPRD)data
set (now called the Clinical Practice Research Datalink [www
.CPRD.com]) was obtained via the Medical Research Council
license. The study protocol was approved by the Indepen-
dentScientificAdvisoryGroupof theUKMedicinesandHealth-
care Products Regulatory Agency.
Cohort
Clinical data, dates of levothyroxine prescriptions, and thy-
rotropin levels were extracted in primary care patients from
the GPRD, which has been well described previously17 and is
the largest computerizeddatabaseof anonymizedmedical rec-
ords from primary care linked with other health care data. It
iswell validated for researchonclinicaldiagnoses18,19 anddrug
exposure and patient safety.20-22
At the time of this study, the GPRD contained computer-
izedmedical records ofmore than 5million persons from508
primarycarepractices throughout theUnitedKingdom.We in-
cludedpersonswhohad initiated levothyroxine treatmentbe-
tween January 1, 2001, and October 30, 2009, and excluded
those who had a history of hyperthyroidism, pituitary dis-
ease, or thyroid surgery; those who were taking thyroid-
altering medication or if the levothyroxine prescription was
related to pregnancy; and those who did not have a thyrotro-
pin level measured within 3months before initiation of levo-
thyroxine.Details of ourdata set areprovided in theeMethods
in the Supplement.
Identification of Thyrotropin and Free Thyroxine Results
Generating the First Levothyroxine Prescription
Westudied incident (first) levothyroxineprescriptions. A thy-
rotropin or free thyroxine (FT4) level was relevant if it oc-
curred within 90 days before levothyroxine initiation.
Ifmore than 1 result was available, then the result closest
to the date of levothyroxine initiation was used. Prescribing
rates were calculated using baseline GPRD denominator data
and were adjusted after removing from the denominator the
person-timeof individualsprescribed levothyroxineafter 2001
(fromthedateof their levothyroxineprescriptionuntil theend
of the study period or their exit from theGPRD). Excluded in-
dividuals (eg, those prescribed levothyroxine in pregnancy)
were also removed from the person-years at risk.
Identification of Factors Potentially Relevant to Prescribing
Levothyroxine at the Time of Initiation of Treatment
Medical codeswere studied for eachpatientwithin60daysbe-
fore the relevant thyrotropin test. Codes regarding symp-
toms, examination findings, diagnoses, clinic appointments,
and investigations were grouped into categories specified a
priori (eTable 3 in the Supplement). For example, the atrial fi-
brillation or tachycardia category had several medical codes,
including atrial fibrillation, AF, and paroxysmal AF pertain-
ing to it. Individuals could be assigned to more than 1 cat-
egory but would only be counted once within a category.
Thyrotropin Levels After Levothyroxine Initiation
Using thedate of the index levothyroxineprescription as time
zero, the thyrotropin levels after levothyroxine therapy were
studied for up to 5 years. Time bandswere split into 6-month
intervals. Individuals couldonlybeassignedonce ineach time
band. If 2 or more thyrotropin values were available for a pa-
tient in the same 6-month period, the later thyrotropin level
was used.We studied thyrotropin values 30 to 36months and
54to60monthsafter levothyroxine initiation.Thyrotropin lev-
els below 0.5 mIU/L were regarded as low, and values below
0.1 mIU/L were regarded as suppressed in keeping with pre-
vious regional UK studies.10,15
Statistical Analysis
Themedian thyrotropin levels at levothyroxine initiationwere
calculated by year between 2001 and 2009. Logistic regres-
sionwasundertaken to assess the odds ratio (OR) for having a
levothyroxine prescription with thyrotropin levels of 10.0
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mIU/L or less using the odds of being prescribed levothyrox-
ine with a thyrotropin level of 10.0 mIU/L or lower in 2001 as
a baseline, with analyses adjusted for sex, clinical character-
istics, and age at levothyroxine initiation.
Univariable logistic regression was also used to estimate
theoddsofdevelopingasuppressed thyrotropin level at5years
after levothyroxine initiation for sex, age,yearof the indexpre-
scription, thyrotropin level at the time of the index levothy-
roxine prescription, and key clinical characteristics before le-
vothyroxine therapy.Multivariable logistic regressionwas then
undertaken, adjusting for sex, age, year of the indexprescrip-
tion of levothyroxine, and thyrotropin level at the time of the
index levothyroxine prescription.
All statistical analyses were performed with commer-
cially available software—STATA, version 12 (StataCorp LP).
Results
Characteristics of Individuals Prescribed Levothyroxine
The flowof patients in our data set is shown in eFigure 1 in the
Supplement.We identified52 298 individualsmatchingour in-
clusion criteria who had a levothyroxine prescription within
90 days after a documented thyrotropin level measurement.
The median age at the time of the index levothyroxine pre-
scription was 59 years (interquartile range, 47-72 years), with
a male-female ratio of 1:3.74.
Prescribing Patterns in Initiation of Levothyroxine Therapy
Overall, the median thyrotropin level before the index levo-
thyroxineprescriptionbetween 2001 and 2009was8.2mIU/L
(interquartile range, 5.9-13.9mIU/L) (Figure 1). Theannualme-
dian thyrotropin level fell during the study period from8.7 to
7.9mIU/L (Figure 2). This decrease reflected a reduction in in-
dividuals treated for an initial thyrotropin level greater than
10.0 mIU/L (42.1% to 35.6%) and a rise in those treated for a
thyrotropin level in the range of 4.0 to 10.0 mIU/L (49.8% to
58.1%) (Table 1). Adjusting for sex, age, key clinical character-
istics before levothyroxine therapy, and the presence of dia-
betesmellitus, hypertension, or raised lipid levels, the OR for
having an index levothyroxine prescription with a thyrotro-
pin level of 10.0mIU/Lor less in 2009comparedwith 2001was
1.30 (95% CI, 1.19-1.42; P < .001). Free thyroxine levels were
available in 34 808 participants (66.6%) at the time of the in-
dex prescription of levothyroxine (eTable 4A, eTable 4B, and
eFigure 2 in the Supplement). The odds of initiation of levo-
Figure 1. Thyrotropin Levels at the Time of the Index Prescription of Levothyroxine
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Figure 2. Median Thyrotropin Levels at the Time of the Index Prescription of Levothyroxine
and Rate of Index Prescriptions by Year
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thyroxine therapy with a thyrotropin level 10.0mIU/L or less
at the endof the study in the subgroupof patientswith anFT4
level in the reference range was slightly lower (OR, 1.17; 95%
CI, 1.00-1.36; P = .05) than in the analysis of thewhole cohort
(OR, 1.30; 95% CI, 1.19-1.42; P < .001).
Between 2001 and 2006, there was a 1.81-fold increase in
the rate of index levothyroxine prescriptions (eTable 1 in the
Supplement).After this time, the rateofnewprescriptionsdid
not substantially change despite a continuing decline in the
median thyrotropin level at the time of the index levothyrox-
ine prescription (Figure 2). Age-standardized rates compar-
ing 2001prescribingwith 2006prescribing revealed that there
was still a 1.79-fold increase in the rate of index levothyrox-
ine prescriptions after the change in age in the data set was
taken into account. Age-stratified rates are given in eTable 2
in the Supplement.
Levothyroxineprescriptionswereusually continued long
term. Overall, 38 939 of 43 057 individuals (90.4%) still in the
GPRD at the end of the study had received a repeat levothy-
roxine prescription during 2009.
Clinical Data Among Individuals Prescribed Levothyroxine
The symptoms and signs recorded in the 60-day period be-
fore initiation of levothyroxine are given in eTable 3 in the
Supplement. The most common symptoms were tiredness
(19.3%),weight gainorobesity (14.0%), anddepression (5.8%).
The median thyrotropin levels among individuals with re-
corded sleep apnea (23.1 mIU/L) or periorbital edema (32.7
mIU/L) were substantially greater than 10.0 mIU/L, consis-
tent with the presence of more profound hypothyroidism.
In 34 808 individuals with an FT4 level available, 10 939
(31.4%)had levothyroxineprescribedwith a thyrotropin level
of 10.0mIU/L or less and a normal FT4 level despite no previ-
ous cardiovascular risk factors or classic hypothyroid symp-
toms, andwerepotentially overtreated. In addition, individu-
als in whom levothyroxine was initiated with a thyrotropin
level in the range of 4.0 to 10.0 mIU/L and a normal FT4 level
rather than a low FT4 level were more likely to be older and
have cardiovascular risk factors but were not more likely to
manifest tiredness, weight gain or obesity, or depression at
baseline (eTable 4A in the Supplement). In contrast, individu-
als prescribed levothyroxine with a thyrotropin level be-
tween4.0and10.0mIU/L insteadofexceeding10.0mIU/Lwere
more likely to be female, have cardiovascular risk factors, and
been older than 70 years when prescribed levothyroxine af-
ter 2004, with trends also observed for tiredness and depres-
sion (eTable 4B in the Supplement).
Thyrotropin Levels After Initiation of Levothyroxine Therapy
Trends in thyrotropin levels after initiation of levothyroxine
therapyare shown inFigure3.Notall individualshadmeasure-
mentof thyrotropin levels repeated regularly. Thedata setwas
created in2010,atwhich timewehadthyrotropin levelsat3 fol-
low-up years in 17 154 individuals (51.5% of those with 3 fol-
low-upyears)andat5 follow-upyears in9252 individuals (39.7%
of thosewith5 follow-upyears).During theperiod6months to
5yearsafter levothyroxine therapy initiation, thepercentageof
thosewithathyrotropin level less than0.1mIU/Lincreasedfrom
2.7% to 5.8%, and the percentage of those with a thyrotropin
level between0.1 and0.5mIU/L increased from6.3% to 10.2%.
This was accompanied by a decrease in those with a thyrotro-
pin levelbetween5.0and10.0mIU/Lfrom29.8%to18.8%.Over-
all, 2.7%of individuals still hada thyrotropin level greater than
10.0mIU/L at 5 years after levothyroxine was initiated.
Individuals’ baseline characteristics seemed to substan-
tially influence the odds of developing suppressed thyrotro-
pin levels at 5 years after levothyroxine initiation (Table 2):
these includedfemalesex (OR, 1.57;95%CI, 1.18-2.08;P = .002),
tiredness (1.51; 1.13-2.01; P = .005) or depression (1.63; 1.02-
2.60;P = .04), and a thyrotropin level at the index levothyrox-
ineprescriptionof less than4.0mIU/L (1.83; 1.35-2.47;P < .001)
or greater than 10.0 mIU/L (2.68; 2.07-3.44; P < .001). Having
cardiovascular risk factors at baseline was generally associ-
ated with reduced odds of a low thyrotropin level at 5 fol-
low-upyears, although thepresenceof atrial fibrillationordia-
betes mellitus had wide CIs that included equality.
Table 1. Thyrotropin Levels Before the Index Prescription of Levothyroxine by Year and by the Odds of Initiating Therapy at Thyrotropin Levels
of 10.0mIU/L or Less Using Prescribing Data of Levothyroxine in 2001 as a Baselinea
Year
Thyrotropin Level, mIU/L Model 1 Model 2 Model 3
<4.0 4.0-10.0 >10.0 OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
2001 8.1 49.8 42.1 1 [Reference] … 1 [Reference] 1 [Reference] …
2002 5.6 53.1 41.3 1.03 (0.94-1.12) .49 1.02 (0.94-1.12) .59 1.02 (0.93-1.11) .68
2003 5.5 53.3 41.2 1.04 (0.95- 1.12) .41 1.04 (0.95-1.13) .45 1.03 (0.94-1.12) .53
2004 6.6 54.3 39.1 1.14 (1.04-1.23) .003 1.14 (1.05-1.24) .002 1.13 (1.04-1.22) .005
2005 5.4 56.0 38.5 1.16 (1.04-1.25) <.001 1.17 (1.08-1.27) <.001 1.14 (1.05-1.24) .001
2006 5.8 57.4 36.7 1.27 (1.15-1.35) <.001 1.27 (1.17-1.38) <.001 1.24 (1.14-1.34) <.001
2007 5.2 57.3 37.4 1.22 (1.11-1.32) <.001 1.23 (1.13-1.34) <.001 1.19 (1.10-1.31) <.001
2008 6.7 55.8 37.5 1.18 (1.11-1.32) <.001 1.24 (1.14-1.35) <.001 1.20 (1.10-1.31 <.001
2009 6.3 58.1 35.6 1.32 (1.20-1.43) <.001 1.34 (1.23-1.46) <.001 1.30 (1.19-1.42) <.001
Abbreviation: OR, odds ratio.
a Among 52 298 individuals. P values are calculated using theWald test. Model 1
gives crude values. Model 2 adjusts for sex and age at the index levothyroxine
sodium prescription. Model 3 adjusts for sex, age at the index levothyroxine
prescription, key clinical characteristics before levothyroxine therapy, and the
presence of diabetes mellitus, hypertension, or raised lipid levels before
levothyroxine initiation.
Threshold for Elevated Thyrotropin Level Treatment Original Investigation Research
jamainternalmedicine.com JAMA Internal Medicine January 2014 Volume 174, Number 1 35
Downloaded From:  by a London Sch of Hygiene & Tropical Medicine User  on 01/19/2018
Copyright 2014 American Medical Association. All rights reserved.
Discussion
Our results showthat theannual rateofnewlevothyroxinepre-
scriptions increased 1.74-fold during the study period. There
was also a decline in themedian thyrotropin threshold at the
time of the index levothyroxine prescription from 8.7 to 7.9
mIU/L, with a 28.0% increase in the odds of having levothy-
roxine initiated at a thyrotropin level of 10.0 mIU/L or less.
This increase in ratewasnot simplydue to an agingpopu-
lationbecause age-adjusted andage-stratified rates alsodem-
onstrated a rise (eTables 1 and 2 in the Supplement). Further-
more, it was not because of shorter prescriptions because we
only counted the first (incident) prescription apatient ever re-
ceived. An increase in case finding due to more thyroid tests
being ordered,4,9,23 in combination with the observed fall in
the thyrotropin threshold for initiationof treatment, could ex-
plain this increase. Because our data set does not contain in-
formation about individuals who never received levothyrox-
ine therapy, we cannot calculate the relative contribution of
these 2 factors.
Although it may only partly account for the overall in-
crease in the number of persons in whom levothyroxine was
prescribed, the reduction in the thyrotropin threshold is im-
portant because it implies that the net benefits of levothyrox-
ine therapy may be more marginal. For example, the highest
age-adjustedandage-stratified ratesofnewlevothyroxinepre-
scribing (evenwith anormal FT4 level)were observed inolder
persons (eTable 2 in the Supplement), who also had the high-
est odds of being prescribed levothyroxine with a thyrotro-
pin level between4.0and 10.0mIU/L (eTable4B in theSupple-
ment). A substantial number of these prescriptions may be
unwarrantedbecausemild thyrotropinelevationsmaybeanor-
mal manifestation of aging.24 Furthermore, evidence shows
that treatment of subclinical hypothyroidism in individuals
older than 70 years has less cardiovascular benefit than that
inyoungerpersons,25 andovertreatment inolderpatientsmay
cause net harm.14,26
The marked increase in new levothyroxine prescriptions
since 2002may have been an unintended consequence of the
Quality and Outcome Framework,27 which required UK pri-
mary care physicians to maintain a database of patients with
hypothyroidism and to monitor thyrotropin levels annually.
Thismayhavedrawnmore attention to thyroid function test-
ing and to levothyroxine therapy, resulting in increased case
finding and enthusiasm to initiate treatment. New prescrip-
tion rates have stabilized since 2007 despite a continued fall
in themedian thyrotropin levels,whichmay indicate that this
enthusiasm for case finding began to wane at this stage.
Most patients (61.1%) in our data set initiated levothyrox-
ine therapy with a thyrotropin level of 10.0 mIU/L or less
(Figure 1).Furthermore, in34 808 individualswithanFT4 level
available, 31.4% had levothyroxine prescribed with a thyro-
tropin level of 10.0 mIU/L or less and a normal FT4 level de-
spite no previous cardiovascular risk factors or classic hypo-
thyroid symptoms. These individuals were potentially
overtreated according to recent guidelines.16 This percentage
may be an overestimate because data about thyroid antibody
status were unavailable, and we could not identify symp-
toms relevant to hypothyroidism before the thyrotropin test
that resulted in the index levothyroxineprescription in47.9%
of individuals.
Free thyroxinevalueswere available in68.3%of individu-
als prescribed levothyroxine with a thyrotropin level be-
tween4.0and10.0mIU/L, and82.7%of this grouphadFT4val-
ueswithin the reference range, consistentwith a diagnosis of
subclinicalhypothyroidism(eTable4AintheSupplement).The
evidence for clinical benefit of treatment in this range out-
side of pregnancy is weak.16 Only 39.4% of individuals pre-
scribed levothyroxine for subclinicalhypothyroidismhadahis-
tory of diabetesmellitus, hypertension, raised lipid levels, or
atrial fibrillation before levothyroxine initiation, with 46.9%
Figure 3. Thyrotropin Levels After Initiation of Levothyroxine
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having these cardiovascular risk factorsordocumented symp-
toms, consistent with hypothyroidism before levothyroxine
therapy (eTables 3 and4A in theSupplement). Although some
data may be unrecorded, up to 50% of individuals with sub-
clinical hypothyroidism may be treated inconsistently with
guidelines. It is somewhat reassuring that in individuals hav-
ing cardiovascular risk factors, levothyroxine was preferen-
tially initiatedamongthosewith thyrotropin levels in the range
of 4.0 to 10.0 mIU/L compared with those not having cardio-
vascular comorbidities (eTable 4A and B in the Supplement).
Contrary toAmericanThyroidAssociation guidelines,16,28 an-
other concern is that 34.6%of individuals prescribed levothy-
roxinewitha thyrotropin levelbetween4.0and10.0mIU/Lhad
only one abnormal thyrotropin reading before initiation of
therapy (eTable 5 in the Supplement). Greater use of confir-
matory testingmight reduceunnecessary prescriptions given
Table 2. Odds of Developing a Suppressed Thyrotropin Level 5 Years After Levothyroxine Therapy by Sex, Age Group, Index Thyrotropin Level,
the Presence of Cardiovascular Risk Factors, and the Clinical Reasons for Prescribing
Characteristic
Thyrotropin Level 0.1-0.5 mIU/L Thyrotropin Level <0.1 mIU/L
OR (95% CI) P Valuea OR (95% CI)b P Valuea,b OR (95% CI) P Valuea OR (95% CI)b P Valuea,b
Sex
Male 1 [Reference] … 1 [Reference] … 1 [Reference] … 1 [Reference] …
Female 1.40 (1.19-1.64) <.001 1.45 (1.23-1.73) <.001 1.55 (1.17-2.04) .002 1.57 (1.18-2.08) .002
Age group at levothyroxine
sodium initiation, y
18 to 45 1 [Reference] … … … 1 [Reference] … 1 [Reference] …
>45 to 70 0.81 (0.70-0.93) .003 0.82 (0.70-0.95) .009 0.71 (0.58-0.89) .002 0.76 (0.61-0.94) .01
>70 to 99 0.52 (0.44-0.62) <.001 0.54 (0.45-0.65) <.001 0.38 (0.28-0.51) <.001 0.41 (0.30-0.55) <.001
Year of index prescription
2001 1 [Reference] … 1 [Reference] … 1 [Reference] … 1 [Reference] …
2002 0.95 (0.80-1.14) .64 0.97 (0.80-1.18) .78 1.03 (0.75-1.39) .87 1.06 (0.78-1.45) .70
2003 0.97 (0.82-1.16) .79 0.98 (0.82-1.18) .86 1.30 (0.98-1.72) .07 1.37 (1.03-1.82) .03
2004 0.75 (0.63-0.90) .002 0.78 (0.65-0.94) .009 0.91 (0.68-1.22) .53 0.97 (0.72-1.30) .83
Index thyrotropin level, mIU/L
<4.0 1.49 (1.24-1.79) <.001 1.44 (1.20-1.72) <.001 1.96 (1.46-2.64) <.001 1.83 (1.35-2.47) <.001
4.0 to 7.0 1 [Reference] … 1 [Reference] … 1 [Reference] … 1 [Reference] …
>7.0 to 10.0 1.18 (0.98-1.42) .08 1.19 (0.99-1.41) .002 1.21 (0.87-1.69) .24 1.22 (0.88-1.71) .21
>10.0 2.54 (2.19-2.94) <.001 2.82 (2.22-2.99) <.001 2.64 (2.05-3.39) <.001 2.68 (2.07-3.44) <.001
Presence of atrial fibrillation
No 1 [Reference] … … … 1 [Reference] … 1 [Reference] …
Yes 0.72 (0.53-0.98) .04 0.87 (0.63-1.20) .40 0.32 (0.15-0.68) .003 0.42 (0.20-0.90) .03
Hypertension or raised
lipid levels
No 1 [Reference] … … … 1 [Reference] … 1 [Reference] …
Yes 0.70 (0.61-0.80) <.001 0.81 (0.71- 0.94) .004 0.55 (0.44-0.71) <.001 0.68 (0.53-0.87) .002
Presence of diabetes mellitus
No 1 [Reference] … 1 [Reference] … 1 [Reference] … 1 [Reference] …
Yes 0.63 (0.48-0.83) .001 0.81 (0.61-1.07) .15 0.59 (0.37-0.95) .03 0.78 (0.48-1.27) .32
Free thyroxine level
at levothyroxine initiation
Normal 1 [Reference] … 1 [Reference] … 1 [Reference] … 1 [Reference] …
Low 2.02 (1.73-2.36) <.001 1.60 1.36-1.89 <.001 1.81 (1.41-2.34) .001 1.37 (1.04-1.81) .02
Clinical reason for
thyrotropin measurement
Depression 1.91 (1.41-2.58) <.001 1.64 (1.19-2.27) .003 1.86 (1.18-2.95) .008 1.63 (1.02-2.60) .04
Tiredness 1.51 (1.25-1.82) <.001 1.56 (1.28-1.89) <.001 1.69 (1.27-2.24) <.001 1.51 (1.13-2.01) .005
Weight gain or obesity 1.31 (1.05-1.63) .02 1.26 (1.00-1.59) .05 1.10 (0.75-1.62) .61 1.03 (0.70-1.51) .89
Peripheral edema 0.78 (0.52-1.17) .23 0.86 (0.57-1.30) .49 0.50 (0.22-1.14) .10 0.57 (0.25-1.29) .18
Menstrual irregularities 1.29 (0.90-1.83) .16 0.99 (0.68-1.42) .94 1.68 (1.01-2.80) .04 1.11 (0.66-1.87) .69
Diabetes review 0.79 (0.55-1.15) .23 0.90 (0.61-1.32) .58 0.66 (0.34-1.29) .23 0.79 (0.40-1.56) .50
General screening 1.15 (0.85-1.58) .36 1.08 (0.78-1.51) .63 0.96 (0.56-1.66) .90 0.99 (0.57-1.72) .99
Abbreviations: ellipsis, not applicable; OR, odds ratio.
a Calculated using theWald test.
bAdjusted for sex, year of the index levothyroxine prescription, age group at the
index prescription, and thyrotropin level at the time of the index prescription
among 9252 individuals with 5 follow-up years.
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that 46% of individuals with a thyrotropin level between 4.5
and 7.0 mIU/L reverted to normal levels within 2 years with-
out treatment.29 This is especially relevant because the indi-
cation for levothyroxine therapy is rarely reviewed once ini-
tiated. In our data set,more than90%of individualswere still
being prescribed levothyroxine at the end of the study.
Setagainst theuncertainpotential forbenefit ina largepro-
portionofpatientswith initiationof levothyroxine therapy, it is
important toexamine thepotential forharm.At5yearsafter le-
vothyroxine initiation, 10.2%ofpatientshada low thyrotropin
level, and5.8%hadasuppressed thyrotropin level. Individuals
withasuppressed thyrotropin level areatpotentially increased
riskofdevelopingosteoporoticfractures15andatrial fibrillation,30
anddata for the increased risk of harm fromsubclinical hyper-
thyroidismare stronger than thedata forpotential benefit from
treatmentof subclinicalhypothyroidism. Individualswithcar-
diac risk factors had reduced odds of developing a suppressed
thyrotropin level, suggesting thatprescriberswereawareof this
risk,but10.6%ofindividualstreatedforsubclinicalhypothyroid-
ismwhohad cardiovascular risk factors ultimatelymanifested
a lowthyrotropin level,whichmayhaveactually increasedtheir
risk. The results of a recentmeta-analysis31 also suggested that
the riskofosteoporosis is increased in individualswitha thyro-
tropin level in the low tonormal range, even if not suppressed,
highlighting thepotential fornetharmwithmarginalovertreat-
ment. Individuals with tiredness or depression at baseline but
not thosewithdiabetesmellitusorweight gainorobesitywere
more likely tobeovertreatedat5years (Table2), raising thepos-
sibilitythattheremaybeanelementof intentional increaseddos-
ingwith levothyroxine rather than a lackof carefulmonitoring
in these individuals.
In theUnitedKingdom, 1.6million individuals areon long-
term levothyroxine regimens, most of whom have been pre-
scribed it forprimaryhypothyroidism.3 If currentpractice con-
tinues, up to 30%of persons receiving levothyroxine therapy
may have been prescribed it without an accepted indication
andwith thepotential for net harm if theydevelop even a low
thyrotropin level (as occurred in 12.2% of individuals pre-
scribed levothyroxine for subclinical hypothyroidism in our
data set). In theUnited States, theprevalence of hypothyroid-
ism is similar to that in the United Kingdom,12 and onemight
expect approximately5million individuals in theUnitedStates
to be on long-term levothyroxine regimens for primary hypo-
thyroidism; ifprescribingpatterns in theUnitedStatesaresimi-
lar, more than 1.6 million individuals may be taking levothy-
roxine with limited evidence of benefit.
The strengths of our study include theuseof a largepopu-
lation-based data set from many different practitioners col-
lected during a long period. Detailed clinical data allowed us
to ascertain cases of primary hypothyroidism and to exclude
individuals who had levothyroxine prescribed as a result of
pregnancy or following treatment of hyperthyroidism or pi-
tuitary disease. In addition, the use of electronicmedical rec-
ords by UK primary care physicians to issue prescriptions
makes it unlikely that prescriptions of levothyroxine were
missed. Similarly, almost all laboratories sentbiochemicaldata
electronically by 2000, so few thyrotropin results were un-
available,andtranscriptionerrorswereeliminated.Wealsohad
substantial data on cardiovascular risk factors and symptoms
before initiation of levothyroxine therapy to enable us to in-
vestigate the appropriateness of levothyroxine prescriptions.
The limitations of our study include the lackof data about
individuals who did not receive a levothyroxine prescription
and the absence of reliable data about thyroid peroxidase an-
tibody titers. Furthermore, data on FT4 measurements were
unavailable in all patients because this estimation is not al-
ways routine practice, and follow-up thyrotropin valueswere
only available in 39.7%of the cohort at 5 years.Hence, the po-
tential for bias exists in the subgroups of individuals ana-
lyzed; however, no differences were observed in sex or age
groupbetween thosewithFT4 levels available and thosewith-
out (eTable4A in theSupplement). The thyrotropinassayused
varied between laboratories, and we were unable to account
for this, althoughmost assays have similar thresholds for de-
fining low or suppressed thyrotropin levels. Finally, we were
unable to identify and exclude fromourdenominator data in-
dividualswhowereprescribed levothyroxinebefore 2001 (and
hence, not at risk of receiving another first levothyroxinepre-
scription). We were also unable to remove from the denomi-
natorperson-years for individuals excludedby theGPRD in the
creation of our data set. However, we consider that the influ-
ence of this factor on the accuracy of our results is likely to be
small, particularly with regard to the relative rate.
In summary, our results suggest that there is widespread
prescribing of levothyroxine for borderline thyrotropin levels
among individualswith limitedevidenceofbenefit. Thisprac-
tice may be harmful given the high risk of developing a sup-
pressed thyrotropin level after treatment. While thyroidolo-
gists are still debating whether subclinical hypothyroidism
shouldbemorewidely treated, it is increasingly apparent that
this is already happening in primary care. Randomized con-
trolled trialswith sufficient power to assess the health conse-
quences of borderline or subclinical hypothyroidism and its
treatment are urgently needed to refine current levothyrox-
ine prescribing and to indicate the balance of risks and ben-
efits of current practice.
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